Pimecrolimus (Topical)
Pimecrolimus Topical — Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Mild-to-moderate atopic dermatitis | Adults and children ≥2 years (non-immunocompromised) | Second-line monotherapy | FDA Approved |
Pimecrolimus 1% cream is FDA-approved exclusively for mild-to-moderate atopic dermatitis as second-line therapy in non-immunocompromised patients aged 2 years and older who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. Unlike tacrolimus ointment (approved for moderate-to-severe AD), pimecrolimus is positioned for milder disease. It is available as a single 1% cream formulation, making dosing straightforward. As a cream vehicle, it is cosmetically more acceptable than tacrolimus ointment and is well suited for facial and sensitive skin areas where topical steroids pose atrophy risk. The 2014 AAD guidelines recommend topical calcineurin inhibitors with Level of Evidence I and Strength of Recommendation A for atopic dermatitis.
Seborrheic dermatitis: Randomised controlled trial data support pimecrolimus 1% cream for facial seborrheic dermatitis, with efficacy comparable to moderately potent topical corticosteroids. Evidence quality: High (RCT).
Vitiligo: Used as an alternative to tacrolimus for facial repigmentation, although evidence suggests tacrolimus 0.1% may be more effective. Evidence quality: Moderate (open-label studies, consensus).
Oral lichen planus: Applied directly to oral mucosal erosions; some evidence supports symptom relief. Evidence quality: Low to Moderate (case series, small studies).
Allergic contact dermatitis, inverse psoriasis, perioral dermatitis: Used when topical corticosteroids are contraindicated or have caused adverse effects. Evidence quality: Low to Moderate.
Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild-to-moderate AD — adults and children ≥2 years | 1% cream BID | Thin layer to affected areas BID | 1% BID | Apply to affected areas only; stop when signs/symptoms (itch, rash, redness) resolve Single strength available — no dose titration needed |
| AD — facial, periorbital, and neck involvement | 1% cream BID | Thin layer BID | 1% BID | Preferred over topical corticosteroids on face/eyelids/neck to avoid steroid-induced atrophy or periocular side effects Cream vehicle is cosmetically elegant for visible areas |
| AD — early intervention (flare prevention) | 1% cream BID at first signs | Apply at earliest signs of flare (itch, erythema) | 1% BID | 1-year trial showed early intervention reduced flare progression in >50% of patients (Wahn 2002) and significantly reduced corticosteroid use In the 1-year safety trial, 43% of pimecrolimus-treated patients vs 68% vehicle patients used corticosteroids (FDA PI) |
| AD — steroid-sparing switch | 1% cream BID | Thin layer BID | 1% BID | Initiated when topical corticosteroids cause local adverse effects or are inadequate for steroid-sensitive sites Can be used sequentially with topical steroids; no washout period required |
| Re-evaluation if no improvement | Reassess at 6 weeks | If no improvement within 6 weeks, re-examine and confirm diagnosis; some conditions (e.g., CTCL) can mimic AD FDA PI mandates clinical reassessment at 6 weeks | ||
Pimecrolimus 1% cream is indicated for mild-to-moderate AD, while tacrolimus ointment (0.03%/0.1%) is for moderate-to-severe AD. Pimecrolimus has a lower incidence of application-site burning (8–26%) compared with tacrolimus (up to 58%) and is formulated as a cream rather than ointment, offering better cosmetic acceptability. However, tacrolimus is considered more potent, with anti-inflammatory efficacy comparable to a moderately potent topical corticosteroid, whereas pimecrolimus is less potent. For patients intolerant of tacrolimus-related burning, pimecrolimus is a reasonable alternative even in moderate disease, though this constitutes off-label use.
Pharmacology
Mechanism of Action
Pimecrolimus is an ascomycin macrolactam derivative that acts as a selective calcineurin inhibitor. It binds with high affinity to the intracellular immunophilin macrophilin-12 (FKBP-12). The resulting pimecrolimus–FKBP-12 complex inhibits calcineurin, preventing dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NF-AT). This blocks transcription of pro-inflammatory cytokines, including IL-2, IL-4, IL-10, and IFN-γ, from both Th1 and Th2 cells. Pimecrolimus also inhibits the release of preformed inflammatory mediators from mast cells upon IgE/antigen stimulation. Notably, unlike tacrolimus, pimecrolimus does not significantly affect Langerhans cell viability or function, which may contribute to a more selective immunomodulatory profile with preserved local immune surveillance. Like tacrolimus, pimecrolimus does not cause skin atrophy because it does not affect fibroblast collagen synthesis, making it safe for long-term intermittent use on steroid-sensitive skin sites.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Topical absorption negligible; blood levels consistently <2 ng/mL in adults (13–62% BSA) and <2 ng/mL in 60% of pediatric samples below LOQ (0.5 ng/mL); permeation through skin lower than tacrolimus due to greater lipophilicity and higher non-specific skin protein binding | Systemic immunosuppression is not expected; even lower systemic exposure than tacrolimus due to 3-fold greater skin protein binding and ~9-fold lower unbound plasma fraction |
| Distribution | 99.6% plasma protein-bound (primarily lipoproteins); unbound fraction ~0.4% (vs ~3.7% for tacrolimus); high tissue and erythrocyte distribution (oral data) | Very low free fraction further limits systemic pharmacologic activity; preferential binding to lipoproteins (unlike albumin-bound tacrolimus) may contribute to different tissue distribution |
| Metabolism | Hepatic via CYP3A4/5; multiple oxidative O-demethylations and hydroxylations; metabolites have low calcineurin inhibition activity and do not contribute meaningfully to pharmacological effect | CYP3A4 inhibitors are a theoretical concern only in patients with extensive skin disease and compromised barrier; metabolites are pharmacologically inactive |
| Elimination | Predominantly faecal (~78% of dose); urinary ~2.5%; no parent drug in urine; elimination t½ ~62 h (oral data); no accumulation with repeated topical application | Long systemic half-life is clinically irrelevant for topical use given negligible absorption; absence of parent drug in urine confirms extensive hepatic metabolism |
Side Effects
Adverse event data are from three pivotal phase 3 pediatric trials (1,114 subjects ages 2–17), two phase 3 infant trials (436 subjects ages 3–23 months), one active-comparator adult trial, and additional safety studies, as reported in the FDA prescribing information for Elidel. Incidence rates below are from the FDA PI unless otherwise noted.
| Adverse Effect | Incidence (Pimecrolimus vs Vehicle) | Clinical Note |
|---|---|---|
| Nasopharyngitis | 26% vs 21% (1-year pediatric) | Most common overall AE in long-term trials; likely reflects seasonal infections in pediatric AD population rather than direct drug effect |
| Headache | 14% vs 9% (short-term); 25% vs 16% (1-year) | More frequent in pimecrolimus groups across trials; usually mild and self-limiting |
| Cough | 16% vs 11% (1-year pediatric) | Upper respiratory symptom; attributable primarily to the AD population rather than the drug itself |
| Pyrexia (fever) | 13% vs 5% (1-year pediatric) | Reported significantly more often than vehicle in paediatric trials; monitor for intercurrent infections |
| Influenza | 13% vs 4% (1-year pediatric) | Seasonal variation likely confounds; however, the differential over vehicle is notable |
| Application-site burning | 10% vs 13% (short-term pediatric); 8–26% (adults, range across trials) | Most common local reaction; notably LOWER than with tacrolimus (up to 58%). Transient; resolves within the first week as skin barrier heals. In 1-year pediatric safety trial, incidence was 9% (vs 7% vehicle) |
| Adverse Effect | Incidence (Pimecrolimus vs Vehicle) | Clinical Note |
|---|---|---|
| Pharyngitis | 8% vs 3% (1-year pediatric) | Sore throat reported more frequently; consider concurrent viral illness |
| Viral infection | 7% vs 1% (1-year pediatric) | Includes various viral exanthems and infections; notably higher than vehicle |
| Herpes simplex | 1–10% | Increased risk of HSV infections compared with vehicle in children (relative risk 2.5, 95% CI 1.2–5.8, p=0.017 per Langley 2007 safety review); counsel patients with history of recurrent herpes |
| Folliculitis | 1–10% | Inflamed hair follicles at application site; reported in pivotal trials at low frequency |
| Impetigo / skin infection | 1–10% | Increased incidence of impetigo, superinfection, and infected AD noted in 1-year pediatric safety trial; AD patients have baseline susceptibility to S. aureus colonisation |
| Alcohol-related facial flushing | Post-marketing | Skin flushing after alcohol consumption reported in post-marketing surveillance; self-limiting; same class effect as with tacrolimus |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Eczema herpeticum | 0.8% (9/843 in children 2–17) | Any time during treatment | Discontinue pimecrolimus; start systemic antiviral (aciclovir/valaciclovir) immediately; dermatology referral |
| Malignancy (skin cancer, lymphoma) — theoretical risk | Very rare (causal link not established) | Post-marketing; long-term | Avoid continuous long-term use; limit UV exposure; skin examinations; FDA boxed warning in effect. A 2023 Lancet systematic review/meta-analysis found no increased cancer risk with moderate certainty |
| Anaphylactic reactions / angioedema | Very rare (post-marketing) | Any time | Discontinue immediately; emergency management; permanent contraindication if confirmed |
| Varicella zoster / herpes zoster | Uncommon | Any time during treatment | Evaluate risk-benefit; initiate antiviral therapy; consider temporary discontinuation until infection resolves |
Pimecrolimus is generally better tolerated locally than tacrolimus. Application-site burning, the most common reason for TCI discontinuation, occurs at lower rates with pimecrolimus (8–26%) compared with tacrolimus (up to 58%). In the 1-year pediatric flare-prevention trial (Wahn 2002), the most common application-site reaction was burning at 10.5% (vs 9.3% control), and there were no major differences in the duration or severity of local reactions between treatment and control groups.
Drug Interactions
Potential interactions between pimecrolimus cream and other drugs, including immunisations, have not been systematically evaluated (FDA PI). Due to the very low blood levels of pimecrolimus detected after topical application, systemic drug interactions are not expected but cannot be ruled out. Pimecrolimus is metabolised by CYP3A4/5.
Monitoring
-
Clinical Response
6-week review
Routine If no improvement within 6 weeks, re-examine and confirm the diagnosis. Conditions such as cutaneous T-cell lymphoma can mimic atopic dermatitis (FDA PI). Stop treatment when symptoms resolve. -
Skin Examination
Each visit
Routine Assess for secondary skin infections (bacterial, viral, fungal). Check for new or changing skin lesions given the theoretical malignancy concern in the boxed warning. No skin atrophy expected (unlike topical steroids). -
Viral Infections
As needed
Trigger-Based Monitor for eczema herpeticum (0.8% in pediatric trials), herpes simplex, and varicella zoster. Pimecrolimus is independently associated with increased herpes simplex risk in children (RR 2.5). Discontinue and treat if viral infection develops. -
Blood Monitoring
Not required
Routine No recommendation for routine blood monitoring with topical pimecrolimus (StatPearls, AAD Level II/Recommendation B). Systemic absorption is negligible at standard doses. -
Sun Exposure
Ongoing
Routine Advise patients to minimise UV exposure. No phototoxicity or photoallergenicity detected in clinical trials, but long-term interaction with UV damage is unknown.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to pimecrolimus or any excipient (benzyl alcohol, cetyl alcohol, citric acid, oleyl alcohol, propylene glycol, sodium cetostearyl sulphate, stearyl alcohol, triglycerides).
- Children under 2 years of age — not recommended per FDA boxed warning; long-term effects on developing immune system unknown.
Relative Contraindications (Specialist Input Recommended)
- Netherton syndrome or other skin diseases with potential for increased systemic absorption — not recommended (FDA PI).
- Generalised erythroderma — safety not established.
- Pre-malignant or malignant skin conditions — some malignancies (e.g., CTCL) may mimic AD; avoid application to known malignant lesions.
- Immunocompromised patients or those on systemic immunosuppressive therapy — safety and efficacy not studied; should not be used.
- Active cutaneous infections at proposed treatment sites — bacterial or viral infections must be resolved before initiating pimecrolimus.
Use with Caution
- Pregnancy — Category C; animal studies showed embryotoxicity at high oral doses. No adequate human studies. Use only if benefit clearly outweighs risk.
- Lactation — unknown whether excreted in human milk after topical use. Decision to discontinue nursing or drug should be made considering importance of the drug to the mother.
- Occlusive dressings — safety under occlusion not evaluated; may promote systemic absorption. Avoid use with occlusive dressings.
Although a causal relationship has not been established, rare cases of malignancy (including skin cancer and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including pimecrolimus cream. Therefore: continuous long-term use should be avoided and application limited to areas of involvement with atopic dermatitis; pimecrolimus cream is not indicated for use in children under 2 years of age; and pimecrolimus cream should be used as second-line therapy for patients who have failed or cannot use other topical treatments. A Medication Guide must be dispensed with each prescription. A 2023 systematic review and meta-analysis in The Lancet Child & Adolescent Health found no increased cancer risk with moderate certainty, though the black box warning remains in effect.
Patient Counselling
Purpose of Therapy
Pimecrolimus cream is a non-steroid prescription treatment for mild-to-moderate eczema (atopic dermatitis). It works by calming the overactive immune response in the skin. Unlike steroid creams, pimecrolimus does not thin the skin, making it particularly useful for sensitive areas like the face, around the eyes, and neck. It is used when other prescription treatments have not worked well enough or are not suitable.
How to Apply
Wash and dry your hands. Apply a thin layer of cream to the affected skin areas only, twice a day. Rub in gently. Wash hands after applying (unless hands are the treated area). After the cream has been absorbed, you may apply moisturisers. Do not cover treated areas with bandages or wraps. Do not apply near eyes, mouth, or genitals (wipe off and rinse with cold water if accidental contact occurs).
Sources
- ELIDEL (pimecrolimus) Cream, 1% — FDA Prescribing Information (2014 revision). accessdata.fda.gov Primary FDA label with most recent adverse event data, pharmacokinetics, pivotal trial results for pediatric and adult populations, and boxed warning text.
- ELIDEL (pimecrolimus) Cream, 1% — FDA Prescribing Information (2010 revision). accessdata.fda.gov Earlier FDA label with detailed monkey IRLD study data and embryofetal development study results.
- FDA Safety Communication: Pimecrolimus (marketed as Elidel Cream) Information. fda.gov FDA safety page covering the 2006 boxed warning update, malignancy concern, and second-line therapy designation for both Elidel and Protopic.
- Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1):e2. doi:10.1542/peds.110.1.e2 Landmark 1-year paediatric trial (713 patients, 2–17 years) demonstrating flare prevention with early intervention; established the steroid-sparing role of pimecrolimus.
- Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495–504. doi:10.1067/mjd.2002.122187 Phase 3 trial establishing safety and efficacy of pimecrolimus 1% cream in paediatric mild-to-moderate AD.
- Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003;111(5):1153–1168. doi:10.1067/mai.2003.1492 Comprehensive clinical review of pimecrolimus pharmacology, mechanism of action, and pivotal trial data in adults and children.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023 AAD guideline positioning TCIs as second-line therapy; Level of Evidence I, Strength A for use in AD; recommends pimecrolimus for mild-to-moderate disease.
- Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7(1):13–25. doi:10.1016/S2352-4642(22)00283-8 High-quality systematic review and meta-analysis finding no increased cancer risk with TCIs with moderate certainty; key evidence informing clinical reassurance about the boxed warning.
- Pimecrolimus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. ncbi.nlm.nih.gov/books/NBK545135 Comprehensive NCBI reference covering pimecrolimus mechanism of action, FKBP-12 binding, contraindications, monitoring recommendations, and AAD guideline evidence levels.
- Langley RG, Luger TA, Cork MJ, Schneider D, Paul C. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology. 2007;215(Suppl 1):27–44. doi:10.1159/000102118 Safety review reporting application-site burning rates (16.1 events per 1,000 patient-months in adults) and herpes simplex relative risk (2.5 in children vs vehicle).
- Zollinger M, Keller TH, Gschwind HP, et al. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006;34(5):765–774. doi:10.1124/dmd.105.007732 Definitive PK study in humans establishing half-life (~62 h), CYP3A4/5-mediated metabolism, faecal excretion (~78%), and metabolite activity profile.
- Billich A, Aschauer H, Aszodi A, et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Br J Dermatol. 2004;151(1):206–213. doi:10.1111/j.1365-2133.2004.06082.x Key study establishing the lower unbound plasma fraction of pimecrolimus (~0.4%) vs tacrolimus (~3.7%), explaining lower systemic exposure after topical application.
- Schmitt J, von Kobyletzki L, Svensson A, et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis. Br J Dermatol. 2011;164(2):415–428. doi:10.1111/j.1365-2133.2010.10030.x Systematic review supporting proactive treatment with TCIs for flare prevention; provides comparative efficacy and tolerability data for pimecrolimus and tacrolimus.